Pricing

Australia Reviews PBS Pricing Framework Amid Industry Dispute Over Benchmarks

Yuvraj — Fri, 17 Jul 2026 11:30:51 +0000

The Australian government is currently navigating a significant period of reassessment regarding its national drug reimbursement model, as tensions between global pharmaceutical manufacturers and health regulators reach a critical juncture. At the center of this dispute is the Pharmaceutical Benefits Scheme (PBS), a system that has long served as the primary mechanism for ensuring affordable […]

The post Australia Reviews PBS Pricing Framework Amid Industry Dispute Over Benchmarks first appeared on World Pharma Today.

Germany to Double Mandatory Drug Rebates to 15.5 Percent

Yuvraj — Tue, 14 Jul 2026 13:37:36 +0000

As European nations seek to stabilize their national health systems, the resulting regulatory changes are prompting a reassessment of market priority and supply chain reshoring. In a significant escalation of this trend, German lawmakers have finalized a sweeping health insurance reform package that more than doubles the mandatory drug rebates that manufacturers must pay on […]

The post Germany to Double Mandatory Drug Rebates to 15.5 Percent first appeared on World Pharma Today.

AstraZeneca UK Investment Resumes with £300m Commitment

Yuvraj — Fri, 01 May 2026 09:06:42 +0000

In a reversal of its earlier stance, AstraZeneca has confirmed a £300m commitment to the UK, marking a renewed push into domestic operations after previously halting major projects. The announcement, delivered in Parliament by Keir Starmer, signals a shift in direction following concerns over the UK’s business climate, including access to new medicines through the […]

The post AstraZeneca UK Investment Resumes with £300m Commitment first appeared on World Pharma Today.

Trump Announces 100% US Pharma Tariffs for Patented Drugs

Yuvraj — Sat, 04 Apr 2026 08:55:16 +0000

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements with the US government or committed to establishing manufacturing operations domestically. Positioned as a national security […]

The post Trump Announces 100% US Pharma Tariffs for Patented Drugs first appeared on World Pharma Today.

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

Yuvraj — Tue, 03 Mar 2026 13:10:36 +0000

The Centers for Medicare & Medicaid Services (CMS) in the US has moved to extend the enrolment window for its GENEROUS pilot programme, an initiative aimed at introducing most-favoured-nation (MFN) pricing for outpatient drugs reimbursed by Medicaid. The agency has revised the participation deadline, shifting it from the end of this month to 30th April. […]

The post CMS Extends GENEROUS MFN Drug Pricing Deadline to April first appeared on World Pharma Today.

CMS Unveils a New Voluntary Access Programme For GLP-1

Yuvraj — Fri, 02 Jan 2026 13:01:53 +0000

In the most recent of a string of announcements ahead of the holiday season, Centers for Medicare & Medicaid Services (CMS) has unveiled a new voluntary access programme which aims to widen the usage of GLP-1 agonist medicines when it comes to diabetes as well as obesity via Medicare and Medicaid. Notably, the Better Approaches to […]

The post CMS Unveils a New Voluntary Access Programme For GLP-1 first appeared on World Pharma Today.

Novartis to Lower Innovative Medicines Price in the US

Yuvraj — Fri, 26 Dec 2025 06:57:43 +0000

Novartis, which is a leading global innovative medicines company, went ahead and announced on December 19, 2025, that it has reached an agreement along with the US government that aims to lower innovative medicines price in the US and also support the ongoing US investment when it comes to manufacturing, research, and development. Apparently, Novartis has voluntarily […]

The post Novartis to Lower Innovative Medicines Price in the US first appeared on World Pharma Today.

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

Yuvraj — Fri, 26 Dec 2025 06:52:11 +0000

President Donald Trump on December 19, 2025, said that his administration has reached agreements with nine additional pharmaceutical companies, therefore extending a campaign that is aimed at decreasing the prescription drug prices for certain Americans while at the same time, temporarily shelving the threatened import tariffs. Notably, these latest agreements bring the total to 14 […]

The post New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices first appeared on World Pharma Today.

Trump To Exempt UK-Origin Pharmaceuticals from Tariffs

Yuvraj — Fri, 05 Dec 2025 07:27:41 +0000

The Trump administration has lined up yet another country-specific trade agreement, and this time it is going to be with the U.K., which confers the biggest break on pharmaceutical import tariffs yet with Washington. For its part, the U.K., which has indeed faced tough policy scrutiny from the biopharma industry in the recent months, is […]

The post Trump To Exempt UK-Origin Pharmaceuticals from Tariffs first appeared on World Pharma Today.

FDA Looks to Accelerate Biosimilar Drug Development

Yuvraj — Tue, 25 Nov 2025 13:33:37 +0000

The FDA has gone on to propose certain new policies in order to accelerate biosimilar drug development and at the same time also lower the cost pertaining to biosimilar agents when it comes to cancer as well as any other serious illnesses. These policies go on to include major updates so as to simplify the biosimilarity […]

The post FDA Looks to Accelerate Biosimilar Drug Development first appeared on World Pharma Today.